Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 3
2011 3
2012 4
2013 3
2014 5
2015 2
2016 4
2017 9
2018 10
2019 9
2020 13
2021 20
2022 22
2023 19
2024 21
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruysscher D; ETOP/IFCT 4-12 STIMULI Collaborators. Peters S, et al. Ann Oncol. 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. Epub 2021 Sep 23. Ann Oncol. 2022. PMID: 34562610 Free article. Clinical Trial.
Software-assisted structured reporting and semi-automated TNM classification for NSCLC staging in a multicenter proof of concept study.
Heimer MM, Dikhtyar Y, Hoppe BF, Herr FL, Stüber AT, Burkard T, Zöller E, Fabritius MP, Unterrainer L, Adams L, Thurner A, Kaufmann D, Trzaska T, Kopp M, Hamer O, Maurer K, Ristow I, May MS, Tufman A, Spiro J, Brendel M, Ingrisch M, Ricke J, Cyran CC. Heimer MM, et al. Among authors: tufman a. Insights Imaging. 2024 Oct 28;15(1):258. doi: 10.1186/s13244-024-01836-z. Insights Imaging. 2024. PMID: 39466506 Free PMC article.
Black and Blue.
Kauffmann-Guerrero D, Kahnert K, Pratschke S, Angstwurm M, Tufman A, Huber RM. Kauffmann-Guerrero D, et al. Among authors: tufman a. Respiration. 2017;94(5):465-466. doi: 10.1159/000479703. Epub 2017 Sep 7. Respiration. 2017. PMID: 28877530 No abstract available.
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ; AIM-HIGH investigators. Spigel DR, et al. Lancet Respir Med. 2025 Oct;13(10):887-896. doi: 10.1016/S2213-2600(25)00213-9. Epub 2025 Jun 24. Lancet Respir Med. 2025. PMID: 40578381 Free article. Clinical Trial.
[Evaluation of solitary pulmonary nodules].
Sienel WGR, Fertmann JM, Kauke T, Tufman A, Kovács J, Angele M, Hatz R, Schneider C. Sienel WGR, et al. Among authors: tufman a. MMW Fortschr Med. 2023 May;165(9):58-61. doi: 10.1007/s15006-023-2659-8. MMW Fortschr Med. 2023. PMID: 37155067 Review. German. No abstract available.
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum AK, Purde MT, Abdou MT, Sinnberg T, Hofmeister K, Pop OT, Hasan Ali O, Bauer J, Cheng HW, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer BS, Driessen C, Schürch CM, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy AN, Schneider T, Brutsche MH, Sette A, Lenz TL, Walz J, Rammensee HG, Früh M, Jäger E, Becher B, Tufman A, Nuñez N, Joerger M, Flatz L. Wyss N, et al. Among authors: tufman a. Am J Respir Crit Care Med. 2024 Oct 1;210(7):919-930. doi: 10.1164/rccm.202311-2136OC. Am J Respir Crit Care Med. 2024. PMID: 38626354
[Lung cancer].
Huber RM, Tufman A. Huber RM, et al. Among authors: tufman a. Dtsch Med Wochenschr. 2014 Mar;139(11):545-52; quiz 553-6. doi: 10.1055/s-0033-1349593. Epub 2014 Mar 4. Dtsch Med Wochenschr. 2014. PMID: 24595713 Review. German. No abstract available.
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J, Käsmann L, Karin M, Eze C, Flörsch B, Guggenberger J, Li M, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Taugner J, et al. Among authors: tufman a. Invest New Drugs. 2022 Feb;40(1):163-171. doi: 10.1007/s10637-021-01143-0. Epub 2021 Aug 5. Invest New Drugs. 2022. PMID: 34351518 Free PMC article. Clinical Trial.
147 results